Telescope Innovations Corp. (TELIF)
USD 0.2
(2.36%)
USD 0.2
(2.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -421.78 Thousand CAD | 92.32% |
| 2022 | -5.49 Million CAD | -36.51% |
| 2021 | -4.02 Million CAD | -1489.82% |
| 2020 | -252.97 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 393.65 Thousand CAD | 188.39% |
| 2023 Q2 | 85.53 Thousand CAD | 137.52% |
| 2023 Q1 | -227.96 Thousand CAD | 66.44% |
| 2023 FY | - CAD | 92.32% |
| 2023 Q4 | -445.34 Thousand CAD | -368.3% |
| 2023 Q3 | 165.98 Thousand CAD | 94.05% |
| 2022 Q4 | -679.29 Thousand CAD | 25.54% |
| 2022 Q3 | -912.24 Thousand CAD | 71.06% |
| 2022 Q2 | -3.15 Million CAD | -322.19% |
| 2022 Q1 | -746.64 Thousand CAD | -35.42% |
| 2022 FY | - CAD | -36.51% |
| 2021 Q3 | -3.29 Million CAD | -2142.43% |
| 2021 FY | - CAD | -1489.82% |
| 2021 Q4 | -551.35 Thousand CAD | 83.27% |
| 2021 Q2 | 161.36 Thousand CAD | 522.29% |
| 2021 Q1 | -38.21 Thousand CAD | -15.63% |
| 2020 Q4 | -33.04 Thousand CAD | 0.0% |
| 2020 Q2 | -33.06 Thousand CAD | 0.0% |
| 2020 FY | - CAD | 0.0% |
| 2019 Q4 | -33.24 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 88.959% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.406% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -76.368% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.342% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 84.05% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 97.572% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.449% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 72.541% |
| Marizyme, Inc. | -34.28 Million USD | 98.77% |
| Genus plc | 73.7 Million USD | 100.572% |
| Pharming Group N.V. | 9.87 Million USD | 104.27% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 71.643% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 88.109% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 95.192% |
| ContraFect Corporation | -64.99 Million USD | 99.351% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 69.911% |
| IMV Inc. | -35.52 Million USD | 98.813% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 81.85% |
| ONE Bio Corp. | 13.61 Million USD | 103.098% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.125% |
| Mesoblast Limited | -62.38 Million USD | 99.324% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 18.582% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 111.808% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.83% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 33.305% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 81.537% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 92.886% |
| Biomind Labs Inc. | -1.03 Million USD | 59.23% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 85.417% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 94.11% |
| Skye Bioscience, Inc. | -13.54 Million USD | 96.887% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 6372.814% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 93.62% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -1587.136% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 90.681% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 89.141% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 97.342% |
| Accustem Sciences Inc. | -3.74 Million USD | 88.742% |
| EV Biologics, Inc. | -1.26 Million USD | 66.713% |
| Q BioMed Inc. | -617.62 Thousand USD | 31.709% |
| GB Sciences, Inc. | -1.41 Million USD | 70.294% |
| Alpha Cognition Inc. | -9.7 Million USD | 95.654% |
| CSL Limited | 4.78 Billion USD | 100.009% |
| Agentix Corp. | -1.37 Million USD | 69.252% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 98.936% |
| Enzolytics Inc. | -2.12 Million USD | 80.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 96.408% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 86.23% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 83.142% |
| argenx SE | -216.02 Million USD | 99.805% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.238% |
| HST Global, Inc. | -5303.00 USD | -7853.687% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 134.658% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 79.495% |
| Halberd Corporation | -74.27 Thousand USD | -467.837% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 104.764% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 211.334% |
| Zenith Capital Corp. | -8.6 Million USD | 95.099% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 71.861% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 82.759% |
| AVAX Technologies, Inc. | -6.11 Million USD | 93.1% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -139.617% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 78.043% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2321.124% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | 59.24% |
| Helix BioMedix, Inc. | -1.04 Million USD | 59.689% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 75.898% |
| Kadimastem Ltd | -2.62 Million USD | 83.928% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 94.416% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -132.917% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 202.304% |
| Cell Source, Inc. | -4.27 Million USD | 90.128% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -14.858% |
| Regen BioPharma, Inc. | 1.46 Million USD | 128.772% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 54.983% |
| Affymax, Inc. | -14.29 Million USD | 97.049% |
| Mobile Lads Corp. | -2.24 Million USD | 81.18% |
| Itoco Inc. | -1.86 Million USD | 77.433% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -11.107% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 62.206% |
| International Stem Cell Corporation | 202 Thousand USD | 308.804% |
| CytoDyn Inc. | -18.02 Million USD | 97.661% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -433.708% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -3349.047% |
| Qrons Inc. | -40.08 Thousand USD | -952.329% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 13.156% |
| SYBLEU INC | -141.57 Thousand USD | -197.931% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 179.969% |
| Rebus Holdings, Inc. | -951 Thousand USD | 55.648% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 60.284% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -701.261% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 82.868% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.824% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -837.298% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 84.595% |
| Neutra Corp. | -181.24 Thousand USD | -132.712% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 97.908% |
| PureTech Health plc | -11.62 Million USD | 96.372% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 97.908% |
| IXICO plc | -707 Thousand USD | 40.342% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 94.512% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.128% |
| CSL Limited | 4.73 Billion USD | 100.009% |
| Cellectis S.A. | -92.63 Million USD | 99.545% |